AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (269 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2009-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patient hasthe patientpatient isdisorderto determine
  Phrases that lowered it: and safetyefficacy andcentergroupreceived
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Sponsor's past trials: 537 (raises risk) · Sponsor's track record
• Has a data monitoring committee: not given (lowers risk) · Design
• Responsible party: not given (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 296 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Number of arms: 4 (lowers risk) · Design
• Sponsor's past termination rate: 6.9% (lowers risk) · Sponsor's track record
• Blinding: quadruple (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Maximum age: 65 (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325 NCT00807937 · started 2008 · scored riskier than 81% of active trials completed
• A Dose-Response Safety Study of ENX-102 in Patients With GAD NCT06653296 · started 2024 · scored riskier than 16% of active trials completed
• A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder NCT05729373 · started 2023 · scored riskier than 31% of active trials completed
• ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder NCT05749055 · started 2023 · scored riskier than 22% of active trials completed
• Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects NCT00616655 · started 2008 · scored riskier than 9% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.